Blackstone Life Sciences, a unit within the firm’s private equity group, made a $337 million investment in Medtronic to help expand development future diabetes technologies.
The . . .
Continue Reading With a Free Trial
Unlock this article instantly, along with the rest of our premium content, newsletters and mandate charts.
Already a subscriber? Log in.